Sutro Biopharma Gross Profit

As of the most recent data (March 2026), STRO shows a gross profit of $72M. That compares with $63M in the prior-year period — up 14.5% year over year. That is below the Healthcare sector average of $65B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, STRO's gross profit is now $72M (was $63M) — a 14.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sutro Biopharma is outperforming or lagging.

The Healthcare sector average gross profit is about $65B. Sutro Biopharma is at $72M, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how STRO stacks up against individual peers as well.

Tracking STRO's gross profit over time shows whether Sutro Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $72M That compares with $63M in the prior-year period — up 14.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Sutro Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $72M) with ownership activity and broader fundamentals.